Literature DB >> 11259369

Protective effects of anti-C5a peptide antibodies in experimental sepsis.

M S Huber-Lang1, J V Sarma, S R McGuire, K T Lu, R F Guo, V A Padgaonkar, E M Younkin, I J Laudes, N C Riedemann, J G Younger, P A Ward.   

Abstract

We evaluated antibodies to different peptide regions of rat C5a in the sepsis model of cecal ligation and puncture (CLP) for their protective effects in rats. Rabbit polyclonal antibodies were developed to the following peptide regions of rat C5a: amino-terminal region (A), residues 1-16; middle region (M), residues 17-36; and the carboxyl-terminal region (C), residues 58-77. With rat neutrophils, the chemotactic activity of rat C5a was significantly inhibited by antibodies with the following rank order: anti-C > anti-M >> anti-A. In vivo, antibodies to the M and C (but not A) regions of C5a were protective in experimental sepsis, as determined by survival over a 10-day period, in a dose-dependent manner. The relative protective efficacies of anti-C5a preparations (in descending order of efficacy) were anti-C > anti-M >> anti-A. In CLP rats, a delay in infusion of antibodies, which were injected at 6 or 12 h after CLP, still resulted in significant improvement in survival rates. These in vivo and in vitro data suggest that there are optimal targets on C5a for blockade during sepsis and that delayed infusion of anti-C5a antibody until after onset of clinical evidence of sepsis still provides protective effects.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11259369     DOI: 10.1096/fj.00-0653fje

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  43 in total

Review 1.  Mechanisms of Hemolysis During Sepsis.

Authors:  Katharina Effenberger-Neidnicht; Matthias Hartmann
Journal:  Inflammation       Date:  2018-10       Impact factor: 4.092

Review 2.  Sepsis, apoptosis and complement.

Authors:  P A Ward
Journal:  Biochem Pharmacol       Date:  2008-09-20       Impact factor: 5.858

3.  Functions of the complement components C3 and C5 during sepsis.

Authors:  Michael A Flierl; Daniel Rittirsch; Brian A Nadeau; Danielle E Day; Firas S Zetoune; J Vidya Sarma; Markus S Huber-Lang; Peter A Ward
Journal:  FASEB J       Date:  2008-06-27       Impact factor: 5.191

4.  Resolvin D2 restores neutrophil directionality and improves survival after burns.

Authors:  Tomohiro Kurihara; Caroline N Jones; Yong-Ming Yu; Alan J Fischman; Susumu Watada; Ronald G Tompkins; Shawn P Fagan; Daniel Irimia
Journal:  FASEB J       Date:  2013-02-21       Impact factor: 5.191

5.  Generation of C5a by phagocytic cells.

Authors:  Markus Huber-Lang; Ellen M Younkin; J Vidya Sarma; Niels Riedemann; Stephanie R McGuire; Kristina T Lu; Robin Kunkel; John G Younger; Firas S Zetoune; Peter A Ward
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

6.  PATHOLOGICAL ASPECTS OF THE ANTI-INFLAMMATORY/IMMUNE SUPPRESSIVE RESPONSE IN SEPSIS AND SHOCK.

Authors:  Alfred Ayala; Yanli Ding; Rebecca J Rhee; Lesley A Doughty; Patrician S Grutkoski; Chun-Shiang Chung
Journal:  Rec Res Dev Immunol       Date:  2003-01-12

Review 7.  Role of C3, C5 and anaphylatoxin receptors in acute lung injury and in sepsis.

Authors:  Markus Bosmann; Peter A Ward
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

8.  Complement Destabilizes Cardiomyocyte Function In Vivo after Polymicrobial Sepsis and In Vitro.

Authors:  Miriam Kalbitz; Fatemeh Fattahi; Todd J Herron; Jamison J Grailer; Lawrence Jajou; Hope Lu; Markus Huber-Lang; Firas S Zetoune; J Vidya Sarma; Sharlene M Day; Mark W Russell; José Jalife; Peter A Ward
Journal:  J Immunol       Date:  2016-08-12       Impact factor: 5.422

9.  Inhibition of complement C5a prevents breakdown of the blood-brain barrier and pituitary dysfunction in experimental sepsis.

Authors:  Michael A Flierl; Philip F Stahel; Daniel Rittirsch; Markus Huber-Lang; Andreas D Niederbichler; L Marco Hoesel; Basel M Touban; Steven J Morgan; Wade R Smith; Peter A Ward; Kyros Ipaktchi
Journal:  Crit Care       Date:  2009-02-06       Impact factor: 9.097

10.  Anticomplement therapy.

Authors:  Prathit A Kulkarni; Vahid Afshar-Kharghan
Journal:  Biologics       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.